Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis

Friday, May 27, 2016 1 min read

Key Takeaway: Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis

Full Press Release Details

Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis.